| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 71 | 2024 | 505 | 19.200 |
Why?
|
| Mucin-5B | 44 | 2023 | 183 | 11.810 |
Why?
|
| Pulmonary Fibrosis | 50 | 2023 | 323 | 8.330 |
Why?
|
| Lung | 91 | 2023 | 3561 | 5.800 |
Why?
|
| Lipopolysaccharides | 53 | 2013 | 823 | 5.770 |
Why?
|
| Genetic Predisposition to Disease | 68 | 2023 | 2086 | 5.240 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2022 | 288 | 5.030 |
Why?
|
| Lung Diseases, Interstitial | 30 | 2023 | 508 | 4.570 |
Why?
|
| Asthma | 40 | 2023 | 2029 | 3.670 |
Why?
|
| Immunity, Innate | 30 | 2019 | 720 | 3.540 |
Why?
|
| Polymorphism, Genetic | 29 | 2022 | 610 | 3.300 |
Why?
|
| Epigenesis, Genetic | 19 | 2022 | 520 | 3.230 |
Why?
|
| Environmental Exposure | 17 | 2019 | 372 | 3.080 |
Why?
|
| Toll-Like Receptor 4 | 33 | 2014 | 287 | 2.910 |
Why?
|
| Pandemics | 11 | 2022 | 1317 | 2.900 |
Why?
|
| Respiratory Mucosa | 18 | 2021 | 251 | 2.890 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2022 | 152 | 2.790 |
Why?
|
| Genome-Wide Association Study | 32 | 2023 | 1177 | 2.780 |
Why?
|
| Dust | 23 | 2018 | 84 | 2.780 |
Why?
|
| Lung Diseases | 19 | 2018 | 701 | 2.770 |
Why?
|
| DNA Methylation | 18 | 2022 | 495 | 2.670 |
Why?
|
| Promoter Regions, Genetic | 25 | 2022 | 1131 | 2.600 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 330 | 2.580 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 338 | 2.470 |
Why?
|
| Membrane Glycoproteins | 16 | 2010 | 430 | 2.430 |
Why?
|
| Genetic Variation | 18 | 2022 | 870 | 2.410 |
Why?
|
| Bleomycin | 12 | 2023 | 228 | 2.400 |
Why?
|
| Receptors, Cell Surface | 15 | 2015 | 355 | 2.310 |
Why?
|
| Humans | 289 | 2024 | 114674 | 2.190 |
Why?
|
| Alveolitis, Extrinsic Allergic | 3 | 2022 | 86 | 2.180 |
Why?
|
| Bronchoalveolar Lavage Fluid | 46 | 2022 | 590 | 2.150 |
Why?
|
| Polymorphism, Single Nucleotide | 33 | 2023 | 1880 | 2.140 |
Why?
|
| Endotoxins | 18 | 2013 | 211 | 2.110 |
Why?
|
| Mice | 103 | 2023 | 14869 | 2.100 |
Why?
|
| Pneumonia | 17 | 2012 | 568 | 1.850 |
Why?
|
| Animals | 134 | 2023 | 31705 | 1.840 |
Why?
|
| Bronchial Hyperreactivity | 18 | 2015 | 95 | 1.790 |
Why?
|
| Zea mays | 13 | 2001 | 39 | 1.730 |
Why?
|
| Respiratory Tract Diseases | 11 | 2010 | 138 | 1.710 |
Why?
|
| Gene Expression | 22 | 2022 | 1421 | 1.710 |
Why?
|
| Gene Expression Regulation | 23 | 2022 | 2320 | 1.690 |
Why?
|
| Crohn Disease | 7 | 2021 | 196 | 1.670 |
Why?
|
| Gene Expression Profiling | 24 | 2022 | 1518 | 1.660 |
Why?
|
| Male | 181 | 2022 | 55589 | 1.620 |
Why?
|
| Female | 157 | 2022 | 59499 | 1.590 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 13 | 1.580 |
Why?
|
| Toll-Like Receptors | 19 | 2018 | 167 | 1.580 |
Why?
|
| Transcriptome | 11 | 2023 | 725 | 1.550 |
Why?
|
| Betacoronavirus | 5 | 2020 | 250 | 1.540 |
Why?
|
| Placenta | 6 | 2022 | 626 | 1.520 |
Why?
|
| Interleukin-6 | 12 | 2022 | 676 | 1.490 |
Why?
|
| Middle Aged | 114 | 2022 | 26735 | 1.410 |
Why?
|
| Genomics | 12 | 2021 | 635 | 1.400 |
Why?
|
| Quantitative Trait Loci | 9 | 2022 | 305 | 1.390 |
Why?
|
| Genotype | 21 | 2018 | 1760 | 1.380 |
Why?
|
| Mice, Inbred C57BL | 47 | 2022 | 4694 | 1.360 |
Why?
|
| Case-Control Studies | 30 | 2022 | 3003 | 1.350 |
Why?
|
| Cytokines | 30 | 2019 | 1841 | 1.350 |
Why?
|
| Rectal Fistula | 2 | 2021 | 21 | 1.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 12 | 2019 | 916 | 1.340 |
Why?
|
| Genetic Loci | 9 | 2022 | 262 | 1.250 |
Why?
|
| Drosophila Proteins | 8 | 2002 | 164 | 1.230 |
Why?
|
| Biomarkers | 13 | 2022 | 3408 | 1.220 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 4 | 2019 | 42 | 1.200 |
Why?
|
| Respiratory Hypersensitivity | 6 | 2018 | 60 | 1.190 |
Why?
|
| Gain of Function Mutation | 4 | 2022 | 30 | 1.190 |
Why?
|
| Mucociliary Clearance | 2 | 2018 | 42 | 1.160 |
Why?
|
| Aged | 69 | 2022 | 19073 | 1.140 |
Why?
|
| Signal Transduction | 26 | 2022 | 4512 | 1.110 |
Why?
|
| Stillbirth | 3 | 2022 | 57 | 1.110 |
Why?
|
| Administration, Inhalation | 26 | 2013 | 641 | 1.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 25 | 2021 | 1140 | 1.080 |
Why?
|
| RNA | 9 | 2022 | 809 | 1.060 |
Why?
|
| Disease Models, Animal | 28 | 2023 | 3535 | 1.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2016 | 740 | 1.040 |
Why?
|
| Pregnancy | 17 | 2022 | 5518 | 1.040 |
Why?
|
| Adult | 88 | 2022 | 30546 | 1.030 |
Why?
|
| Risk Factors | 34 | 2024 | 8632 | 1.020 |
Why?
|
| Epithelium | 4 | 2022 | 295 | 1.000 |
Why?
|
| Smoking | 26 | 2022 | 1383 | 0.970 |
Why?
|
| Lung Transplantation | 6 | 2017 | 246 | 0.960 |
Why?
|
| Mucus | 4 | 2019 | 54 | 0.960 |
Why?
|
| Infant, Newborn | 13 | 2022 | 5045 | 0.940 |
Why?
|
| Phenotype | 26 | 2022 | 2796 | 0.930 |
Why?
|
| Hypersensitivity | 6 | 2014 | 252 | 0.920 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2023 | 24 | 0.890 |
Why?
|
| Occupational Exposure | 10 | 2018 | 255 | 0.890 |
Why?
|
| Genome, Human | 6 | 2021 | 347 | 0.880 |
Why?
|
| RNA, Messenger | 20 | 2021 | 2553 | 0.880 |
Why?
|
| Graft Rejection | 5 | 2007 | 513 | 0.870 |
Why?
|
| Early Diagnosis | 3 | 2022 | 217 | 0.860 |
Why?
|
| Coronavirus | 2 | 2020 | 40 | 0.850 |
Why?
|
| Caenorhabditis elegans | 5 | 2013 | 268 | 0.840 |
Why?
|
| Occupational Diseases | 10 | 2008 | 128 | 0.840 |
Why?
|
| Pulmonary Alveoli | 6 | 2016 | 373 | 0.830 |
Why?
|
| Saccharopolyspora | 1 | 2022 | 6 | 0.820 |
Why?
|
| Sequence Analysis, DNA | 9 | 2023 | 723 | 0.820 |
Why?
|
| Edible Grain | 8 | 2003 | 43 | 0.810 |
Why?
|
| Mutation | 16 | 2022 | 3346 | 0.810 |
Why?
|
| Macrophages | 14 | 2016 | 1262 | 0.800 |
Why?
|
| Perinatal Death | 1 | 2022 | 22 | 0.800 |
Why?
|
| Maternal Exposure | 4 | 2020 | 138 | 0.770 |
Why?
|
| Respiratory System | 7 | 2022 | 137 | 0.770 |
Why?
|
| Cellular Senescence | 2 | 2021 | 152 | 0.770 |
Why?
|
| Inflammation | 26 | 2022 | 2479 | 0.760 |
Why?
|
| Integrins | 1 | 2022 | 79 | 0.760 |
Why?
|
| Mice, Inbred Strains | 14 | 2016 | 396 | 0.750 |
Why?
|
| Chorionic Villi | 1 | 2021 | 16 | 0.750 |
Why?
|
| Placenta Diseases | 1 | 2021 | 13 | 0.750 |
Why?
|
| Mice, Knockout | 21 | 2019 | 2570 | 0.740 |
Why?
|
| Receptors, Immunologic | 3 | 2015 | 201 | 0.730 |
Why?
|
| Pregnancy Outcome | 2 | 2020 | 337 | 0.730 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2019 | 49 | 0.730 |
Why?
|
| Ozone | 6 | 2012 | 99 | 0.730 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2021 | 91 | 0.720 |
Why?
|
| Airway Obstruction | 6 | 2000 | 168 | 0.720 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 4 | 2019 | 24 | 0.720 |
Why?
|
| Placental Insufficiency | 1 | 2022 | 102 | 0.720 |
Why?
|
| Asbestos | 7 | 2012 | 19 | 0.710 |
Why?
|
| Respiratory Function Tests | 17 | 2021 | 522 | 0.710 |
Why?
|
| Neutrophils | 22 | 2012 | 1176 | 0.710 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 26 | 0.700 |
Why?
|
| Nasal Mucosa | 3 | 2017 | 93 | 0.680 |
Why?
|
| Risk Assessment | 11 | 2020 | 2968 | 0.680 |
Why?
|
| Inhalation Exposure | 4 | 2012 | 97 | 0.670 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2019 | 10 | 0.670 |
Why?
|
| Macrophages, Alveolar | 10 | 2009 | 348 | 0.660 |
Why?
|
| Trophoblasts | 1 | 2021 | 163 | 0.660 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2018 | 452 | 0.660 |
Why?
|
| Cysts | 2 | 2019 | 93 | 0.660 |
Why?
|
| Blood Proteins | 2 | 2020 | 231 | 0.650 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 154 | 0.650 |
Why?
|
| Metagenomics | 2 | 2011 | 131 | 0.650 |
Why?
|
| Career Choice | 1 | 2021 | 177 | 0.650 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2019 | 54 | 0.650 |
Why?
|
| Physicians | 2 | 2021 | 772 | 0.650 |
Why?
|
| Mice, Inbred C3H | 14 | 2010 | 239 | 0.630 |
Why?
|
| Lung Injury | 4 | 2021 | 198 | 0.630 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2021 | 25 | 0.620 |
Why?
|
| Alpha-Globulins | 3 | 2009 | 20 | 0.620 |
Why?
|
| Epithelial Cells | 5 | 2022 | 951 | 0.620 |
Why?
|
| Fibrosis | 8 | 2023 | 453 | 0.600 |
Why?
|
| Paraquat | 1 | 2018 | 14 | 0.600 |
Why?
|
| Disease | 3 | 2011 | 85 | 0.600 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2007 | 81 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 663 | 0.600 |
Why?
|
| Herbicides | 1 | 2018 | 24 | 0.590 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2018 | 34 | 0.590 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2021 | 284 | 0.570 |
Why?
|
| Vital Capacity | 18 | 2015 | 255 | 0.570 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 368 | 0.570 |
Why?
|
| Animal Husbandry | 6 | 2021 | 33 | 0.570 |
Why?
|
| Cohort Studies | 19 | 2023 | 4895 | 0.570 |
Why?
|
| Shock, Septic | 4 | 2011 | 186 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2019 | 2285 | 0.560 |
Why?
|
| Neutrophil Infiltration | 4 | 2012 | 96 | 0.560 |
Why?
|
| Air Pollutants, Occupational | 4 | 2009 | 27 | 0.560 |
Why?
|
| Alleles | 9 | 2017 | 789 | 0.550 |
Why?
|
| Interferon-gamma | 7 | 2007 | 719 | 0.550 |
Why?
|
| Complement C3 | 1 | 2018 | 188 | 0.550 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 122 | 0.550 |
Why?
|
| Bronchioles | 1 | 2016 | 22 | 0.550 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2018 | 71 | 0.540 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 295 | 0.540 |
Why?
|
| Methamphetamine | 1 | 2017 | 51 | 0.540 |
Why?
|
| Desmoplakins | 1 | 2016 | 19 | 0.530 |
Why?
|
| Aged, 80 and over | 19 | 2022 | 6347 | 0.530 |
Why?
|
| CpG Islands | 5 | 2020 | 117 | 0.530 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 57 | 0.530 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 98 | 0.520 |
Why?
|
| Sequence Analysis, RNA | 3 | 2019 | 385 | 0.510 |
Why?
|
| Escherichia coli | 12 | 2011 | 720 | 0.510 |
Why?
|
| Urban Population | 3 | 2015 | 397 | 0.510 |
Why?
|
| China | 3 | 2020 | 161 | 0.510 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2022 | 1003 | 0.500 |
Why?
|
| Scleroderma, Systemic | 2 | 2013 | 96 | 0.490 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2019 | 46 | 0.490 |
Why?
|
| Biomedical Research | 4 | 2024 | 585 | 0.490 |
Why?
|
| Allergens | 11 | 2017 | 413 | 0.470 |
Why?
|
| Clinical Competence | 1 | 2021 | 893 | 0.470 |
Why?
|
| GTPase-Activating Proteins | 4 | 2023 | 71 | 0.470 |
Why?
|
| Th2 Cells | 4 | 2012 | 154 | 0.460 |
Why?
|
| Cilia | 3 | 2022 | 162 | 0.460 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2018 | 37 | 0.460 |
Why?
|
| United States | 24 | 2024 | 12182 | 0.460 |
Why?
|
| Immunoglobulin E | 8 | 2015 | 314 | 0.460 |
Why?
|
| Health Care Costs | 1 | 2017 | 381 | 0.460 |
Why?
|
| Forced Expiratory Volume | 18 | 2015 | 475 | 0.450 |
Why?
|
| Young Adult | 17 | 2022 | 10466 | 0.450 |
Why?
|
| Polymerase Chain Reaction | 11 | 2016 | 993 | 0.450 |
Why?
|
| Inhalation | 3 | 2008 | 26 | 0.450 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 493 | 0.450 |
Why?
|
| Aspartic Acid | 1 | 2014 | 77 | 0.450 |
Why?
|
| Environment | 2 | 2006 | 332 | 0.440 |
Why?
|
| Chromosomes, Mammalian | 2 | 2011 | 26 | 0.440 |
Why?
|
| Bronchial Provocation Tests | 7 | 2011 | 51 | 0.430 |
Why?
|
| Colonic Pouches | 3 | 2021 | 14 | 0.430 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 20 | 0.430 |
Why?
|
| Glycine | 1 | 2014 | 152 | 0.430 |
Why?
|
| Interleukin-10 | 4 | 2006 | 299 | 0.430 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 6 | 2024 | 93 | 0.420 |
Why?
|
| Whole Genome Sequencing | 3 | 2023 | 94 | 0.420 |
Why?
|
| Immune Tolerance | 2 | 2013 | 323 | 0.420 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 217 | 0.420 |
Why?
|
| Sarcoidosis | 3 | 2013 | 135 | 0.420 |
Why?
|
| Hypoxia | 2 | 2022 | 958 | 0.420 |
Why?
|
| Gastrointestinal Agents | 3 | 2021 | 60 | 0.420 |
Why?
|
| Hyaluronic Acid | 3 | 2009 | 190 | 0.410 |
Why?
|
| Diffusion of Innovation | 2 | 2018 | 93 | 0.410 |
Why?
|
| Respiratory Mechanics | 4 | 1994 | 56 | 0.410 |
Why?
|
| Precision Medicine | 5 | 2021 | 337 | 0.410 |
Why?
|
| PPAR gamma | 1 | 2013 | 182 | 0.410 |
Why?
|
| Health Status | 4 | 2011 | 722 | 0.400 |
Why?
|
| Telomere | 5 | 2023 | 202 | 0.400 |
Why?
|
| Lipid A | 2 | 2005 | 28 | 0.390 |
Why?
|
| Pouchitis | 2 | 2021 | 5 | 0.390 |
Why?
|
| DNA | 4 | 2022 | 1352 | 0.390 |
Why?
|
| Colitis, Ulcerative | 3 | 2021 | 105 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 681 | 0.390 |
Why?
|
| Retrospective Studies | 12 | 2023 | 12549 | 0.380 |
Why?
|
| RNA Interference | 8 | 2016 | 433 | 0.380 |
Why?
|
| Science | 1 | 2012 | 48 | 0.380 |
Why?
|
| Air Pollutants | 4 | 2013 | 242 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 58 | 0.370 |
Why?
|
| Chronic Disease | 9 | 2021 | 1578 | 0.370 |
Why?
|
| Disease Progression | 12 | 2021 | 2380 | 0.370 |
Why?
|
| Agricultural Workers' Diseases | 3 | 1996 | 23 | 0.370 |
Why?
|
| Asbestosis | 8 | 1994 | 12 | 0.370 |
Why?
|
| Fibroblasts | 5 | 2023 | 838 | 0.360 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 343 | 0.360 |
Why?
|
| Species Specificity | 7 | 2015 | 542 | 0.350 |
Why?
|
| Mucin 5AC | 4 | 2015 | 48 | 0.350 |
Why?
|
| Medicine | 1 | 2012 | 102 | 0.350 |
Why?
|
| Fucosyltransferases | 2 | 2022 | 27 | 0.350 |
Why?
|
| Pulmonary Emphysema | 2 | 2015 | 272 | 0.350 |
Why?
|
| Bone Marrow Transplantation | 3 | 2009 | 239 | 0.350 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 383 | 0.350 |
Why?
|
| Hyaluronan Receptors | 3 | 2009 | 90 | 0.350 |
Why?
|
| Enterobacteriaceae | 4 | 2013 | 32 | 0.350 |
Why?
|
| Lung Diseases, Obstructive | 3 | 2001 | 40 | 0.350 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 1949 | 0.340 |
Why?
|
| Disease Susceptibility | 3 | 2013 | 316 | 0.340 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2013 | 110 | 0.340 |
Why?
|
| Prevalence | 12 | 2022 | 2251 | 0.330 |
Why?
|
| Germ Cells | 1 | 2009 | 57 | 0.330 |
Why?
|
| Receptors, Interleukin-1 Type I | 2 | 2007 | 22 | 0.330 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 429 | 0.320 |
Why?
|
| Caenorhabditis elegans Proteins | 4 | 2013 | 180 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2020 | 386 | 0.320 |
Why?
|
| Immunohistochemistry | 7 | 2015 | 1629 | 0.320 |
Why?
|
| Karyotyping | 1 | 2008 | 102 | 0.320 |
Why?
|
| Chromosome Mapping | 6 | 2011 | 487 | 0.310 |
Why?
|
| Housing, Animal | 1 | 2009 | 42 | 0.310 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 467 | 0.310 |
Why?
|
| Longevity | 1 | 2009 | 137 | 0.310 |
Why?
|
| Flour | 1 | 2008 | 6 | 0.310 |
Why?
|
| Interleukin-1 | 8 | 2003 | 966 | 0.310 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 13 | 0.310 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 22 | 0.310 |
Why?
|
| Mice, Inbred BALB C | 8 | 2015 | 1144 | 0.310 |
Why?
|
| Aspergillosis | 1 | 2008 | 23 | 0.300 |
Why?
|
| DNA, Bacterial | 3 | 2014 | 311 | 0.300 |
Why?
|
| Plasminogen | 1 | 2008 | 33 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 447 | 0.300 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2005 | 106 | 0.300 |
Why?
|
| Genes | 2 | 2006 | 223 | 0.300 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2006 | 66 | 0.300 |
Why?
|
| Ovalbumin | 8 | 2015 | 161 | 0.300 |
Why?
|
| Graft Survival | 3 | 2007 | 446 | 0.300 |
Why?
|
| Transplantation Immunology | 2 | 2005 | 30 | 0.300 |
Why?
|
| Airway Resistance | 4 | 2011 | 29 | 0.290 |
Why?
|
| Genetic Markers | 5 | 2022 | 320 | 0.290 |
Why?
|
| Complement System Proteins | 2 | 2007 | 283 | 0.290 |
Why?
|
| Complement Inactivator Proteins | 1 | 2007 | 40 | 0.290 |
Why?
|
| Streptococcus | 1 | 2007 | 22 | 0.290 |
Why?
|
| Leukocyte Count | 7 | 2009 | 293 | 0.290 |
Why?
|
| Dyspnea | 6 | 2023 | 211 | 0.290 |
Why?
|
| Telomerase | 2 | 2019 | 206 | 0.290 |
Why?
|
| Persian Gulf Syndrome | 3 | 2004 | 10 | 0.280 |
Why?
|
| Bronchoconstriction | 4 | 2011 | 26 | 0.280 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2020 | 203 | 0.280 |
Why?
|
| Base Sequence | 6 | 2017 | 2114 | 0.280 |
Why?
|
| Leukocytes | 3 | 2006 | 276 | 0.280 |
Why?
|
| Fetus | 2 | 2021 | 700 | 0.280 |
Why?
|
| Cell Line | 9 | 2021 | 2637 | 0.280 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 93 | 0.280 |
Why?
|
| Logistic Models | 8 | 2019 | 1841 | 0.270 |
Why?
|
| Total Lung Capacity | 8 | 2015 | 30 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 281 | 0.270 |
Why?
|
| Otitis Media | 2 | 2019 | 142 | 0.270 |
Why?
|
| Prospective Studies | 20 | 2022 | 6219 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2019 | 1842 | 0.270 |
Why?
|
| Sepsis | 3 | 2010 | 509 | 0.270 |
Why?
|
| Constriction, Pathologic | 4 | 2021 | 208 | 0.270 |
Why?
|
| Toxicology | 1 | 2006 | 35 | 0.260 |
Why?
|
| Age Factors | 9 | 2019 | 2894 | 0.260 |
Why?
|
| DNA Helicases | 2 | 2019 | 133 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 1481 | 0.260 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 83 | 0.260 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 4411 | 0.260 |
Why?
|
| Child | 14 | 2022 | 18412 | 0.260 |
Why?
|
| Receptors, CCR5 | 1 | 2006 | 54 | 0.260 |
Why?
|
| Infant | 8 | 2022 | 7961 | 0.260 |
Why?
|
| Colorado | 3 | 2020 | 4099 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 439 | 0.250 |
Why?
|
| Complement Activation | 2 | 2007 | 340 | 0.250 |
Why?
|
| Streptococcal Infections | 1 | 2007 | 131 | 0.250 |
Why?
|
| Multivariate Analysis | 7 | 2019 | 1430 | 0.250 |
Why?
|
| Adolescent | 23 | 2022 | 17841 | 0.250 |
Why?
|
| Mothers | 2 | 2022 | 651 | 0.250 |
Why?
|
| Methacholine Chloride | 8 | 2015 | 47 | 0.250 |
Why?
|
| Hyperoxia | 1 | 2006 | 99 | 0.250 |
Why?
|
| Tobacco Use | 2 | 2023 | 60 | 0.250 |
Why?
|
| Public Health | 1 | 2010 | 433 | 0.250 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 646 | 0.250 |
Why?
|
| Ligands | 3 | 2022 | 562 | 0.250 |
Why?
|
| Gene Frequency | 6 | 2023 | 477 | 0.250 |
Why?
|
| Organizational Objectives | 1 | 2005 | 66 | 0.240 |
Why?
|
| Environmental Health | 1 | 2005 | 30 | 0.240 |
Why?
|
| Mice, Inbred DBA | 4 | 2008 | 174 | 0.240 |
Why?
|
| Inflammation Mediators | 5 | 2019 | 477 | 0.240 |
Why?
|
| Transforming Growth Factor beta1 | 5 | 2007 | 153 | 0.240 |
Why?
|
| Linkage Disequilibrium | 3 | 2016 | 245 | 0.240 |
Why?
|
| Spirometry | 8 | 2015 | 224 | 0.240 |
Why?
|
| Dietary Supplements | 1 | 2008 | 460 | 0.240 |
Why?
|
| Extracellular Matrix | 3 | 2014 | 436 | 0.240 |
Why?
|
| Gram-Negative Bacteria | 3 | 2018 | 66 | 0.240 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2021 | 19 | 0.240 |
Why?
|
| Congresses as Topic | 3 | 2018 | 195 | 0.240 |
Why?
|
| Culture Media | 4 | 2018 | 155 | 0.240 |
Why?
|
| Mutation, Missense | 3 | 2002 | 293 | 0.240 |
Why?
|
| Cell Movement | 2 | 2007 | 869 | 0.230 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 64 | 0.230 |
Why?
|
| Exome | 2 | 2023 | 200 | 0.230 |
Why?
|
| Environmental Illness | 1 | 2004 | 2 | 0.230 |
Why?
|
| Survival Analysis | 4 | 2015 | 1211 | 0.230 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2005 | 116 | 0.230 |
Why?
|
| Pleura | 3 | 1994 | 18 | 0.230 |
Why?
|
| Interleukin-13 | 4 | 2019 | 122 | 0.230 |
Why?
|
| Interleukin-8 | 7 | 2009 | 237 | 0.230 |
Why?
|
| Transcription, Genetic | 4 | 2013 | 1313 | 0.230 |
Why?
|
| Epigenomics | 2 | 2017 | 101 | 0.220 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 106 | 0.220 |
Why?
|
| Genetic Linkage | 3 | 2011 | 294 | 0.220 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2013 | 32 | 0.220 |
Why?
|
| Acute Disease | 6 | 2021 | 911 | 0.220 |
Why?
|
| Chagas Cardiomyopathy | 2 | 2015 | 22 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 797 | 0.220 |
Why?
|
| Regression Analysis | 5 | 2017 | 944 | 0.220 |
Why?
|
| Transcription Factors | 4 | 2021 | 1528 | 0.210 |
Why?
|
| Alveolar Epithelial Cells | 3 | 2019 | 93 | 0.210 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 2023 | 5 | 0.210 |
Why?
|
| Drug Repositioning | 1 | 2023 | 13 | 0.210 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 228 | 0.210 |
Why?
|
| Histones | 2 | 2022 | 535 | 0.210 |
Why?
|
| Dermatitis, Atopic | 2 | 2022 | 307 | 0.210 |
Why?
|
| ROC Curve | 3 | 2019 | 442 | 0.210 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1660 | 0.210 |
Why?
|
| Mucins | 3 | 2019 | 61 | 0.210 |
Why?
|
| Silicosis | 1 | 2023 | 21 | 0.210 |
Why?
|
| Pedigree | 7 | 2019 | 460 | 0.210 |
Why?
|
| Pleural Diseases | 3 | 1993 | 20 | 0.210 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2008 | 46 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2021 | 9088 | 0.200 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 154 | 0.200 |
Why?
|
| Bacterial Infections | 6 | 2013 | 218 | 0.200 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2023 | 91 | 0.200 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 372 | 0.200 |
Why?
|
| Hospitalization | 3 | 2022 | 1752 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 367 | 0.200 |
Why?
|
| Endoscopy | 2 | 2021 | 246 | 0.200 |
Why?
|
| Proteome | 2 | 2017 | 339 | 0.200 |
Why?
|
| Internationality | 1 | 2022 | 143 | 0.200 |
Why?
|
| Blotting, Western | 4 | 2013 | 1147 | 0.200 |
Why?
|
| A549 Cells | 2 | 2021 | 51 | 0.200 |
Why?
|
| Fetal Death | 1 | 2022 | 50 | 0.200 |
Why?
|
| Eosinophils | 5 | 2015 | 278 | 0.200 |
Why?
|
| Peptide Hydrolases | 1 | 2022 | 104 | 0.190 |
Why?
|
| Fibrin | 1 | 2022 | 65 | 0.190 |
Why?
|
| Telemedicine | 2 | 2021 | 662 | 0.190 |
Why?
|
| Monokines | 5 | 2000 | 24 | 0.190 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 122 | 0.190 |
Why?
|
| Tyrphostins | 1 | 2021 | 13 | 0.190 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1075 | 0.190 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 58 | 0.190 |
Why?
|
| Amphiregulin | 1 | 2021 | 21 | 0.190 |
Why?
|
| Immunity | 1 | 2022 | 121 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2018 | 300 | 0.190 |
Why?
|
| Bacteremia | 2 | 2013 | 160 | 0.190 |
Why?
|
| E2F1 Transcription Factor | 2 | 2012 | 57 | 0.190 |
Why?
|
| Carbapenems | 2 | 2011 | 16 | 0.190 |
Why?
|
| Fibrinolysis | 1 | 2003 | 158 | 0.190 |
Why?
|
| Biophysical Phenomena | 1 | 2021 | 63 | 0.190 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2022 | 43 | 0.190 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2021 | 31 | 0.190 |
Why?
|
| Receptors, Interleukin-1 | 4 | 2010 | 228 | 0.190 |
Why?
|
| Keratin-5 | 1 | 2021 | 46 | 0.190 |
Why?
|
| Tennessee | 1 | 2020 | 38 | 0.180 |
Why?
|
| Cell Communication | 1 | 2022 | 280 | 0.180 |
Why?
|
| Office Visits | 1 | 2021 | 79 | 0.180 |
Why?
|
| Antirheumatic Agents | 2 | 2021 | 255 | 0.180 |
Why?
|
| Phagocytosis | 3 | 2013 | 350 | 0.180 |
Why?
|
| Colectomy | 1 | 2021 | 86 | 0.180 |
Why?
|
| Swine | 5 | 2014 | 700 | 0.180 |
Why?
|
| Isoenzymes | 1 | 2001 | 283 | 0.180 |
Why?
|
| Microbiota | 3 | 2018 | 647 | 0.180 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 2539 | 0.180 |
Why?
|
| Doulas | 1 | 2020 | 2 | 0.180 |
Why?
|
| Home Childbirth | 1 | 2020 | 4 | 0.180 |
Why?
|
| Farmers | 1 | 2021 | 42 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2004 | 695 | 0.180 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 2387 | 0.180 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 339 | 0.180 |
Why?
|
| Necrosis | 1 | 2021 | 211 | 0.180 |
Why?
|
| Telomere Homeostasis | 2 | 2017 | 24 | 0.170 |
Why?
|
| Time Factors | 13 | 2018 | 6115 | 0.170 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2017 | 29 | 0.170 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 2763 | 0.170 |
Why?
|
| Binding Sites | 3 | 2021 | 1168 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 541 | 0.170 |
Why?
|
| Cells, Cultured | 9 | 2018 | 3886 | 0.170 |
Why?
|
| Keratin-15 | 1 | 2019 | 12 | 0.170 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2014 | 84 | 0.170 |
Why?
|
| Spleen | 3 | 2012 | 487 | 0.170 |
Why?
|
| Quinazolines | 1 | 2021 | 240 | 0.170 |
Why?
|
| MicroRNAs | 3 | 2014 | 600 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 811 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2021 | 131 | 0.170 |
Why?
|
| Hospital Medicine | 1 | 2021 | 82 | 0.170 |
Why?
|
| Warfare | 1 | 2000 | 75 | 0.170 |
Why?
|
| Survival Rate | 6 | 2019 | 1644 | 0.170 |
Why?
|
| Dilatation | 1 | 2020 | 60 | 0.170 |
Why?
|
| Proteins | 4 | 2015 | 908 | 0.160 |
Why?
|
| Midwifery | 1 | 2020 | 45 | 0.160 |
Why?
|
| Interleukin-4 | 2 | 2015 | 206 | 0.160 |
Why?
|
| Interferon-beta | 2 | 2011 | 79 | 0.160 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 79 | 0.160 |
Why?
|
| Colloids | 1 | 2019 | 56 | 0.160 |
Why?
|
| Particulate Matter | 3 | 2009 | 185 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 118 | 0.160 |
Why?
|
| Chromosomes | 3 | 2008 | 85 | 0.160 |
Why?
|
| alpha-Macroglobulins | 1 | 2019 | 24 | 0.160 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2018 | 4 | 0.160 |
Why?
|
| ERG1 Potassium Channel | 1 | 2018 | 4 | 0.160 |
Why?
|
| Maternal Health Services | 1 | 2020 | 79 | 0.160 |
Why?
|
| Viral Vaccines | 1 | 2020 | 88 | 0.160 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 340 | 0.160 |
Why?
|
| Exoribonucleases | 1 | 2019 | 40 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 223 | 0.160 |
Why?
|
| Biological Products | 2 | 2021 | 166 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2019 | 108 | 0.160 |
Why?
|
| Expectorants | 1 | 2018 | 24 | 0.160 |
Why?
|
| Gastrointestinal Contents | 1 | 1998 | 7 | 0.160 |
Why?
|
| Colistin | 1 | 2018 | 8 | 0.160 |
Why?
|
| Adipokines | 1 | 2019 | 42 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 1999 | 110 | 0.160 |
Why?
|
| Pneumonia, Aspiration | 1 | 1998 | 15 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2018 | 953 | 0.160 |
Why?
|
| Consensus | 4 | 2021 | 537 | 0.160 |
Why?
|
| Smoking Cessation | 2 | 2020 | 374 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 122 | 0.160 |
Why?
|
| RNA Polymerase II | 2 | 2021 | 284 | 0.150 |
Why?
|
| Nasal Lavage Fluid | 2 | 2009 | 11 | 0.150 |
Why?
|
| Lymphocytes | 4 | 2008 | 330 | 0.150 |
Why?
|
| Mass Screening | 2 | 2018 | 1004 | 0.150 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2019 | 84 | 0.150 |
Why?
|
| Hedgehog Proteins | 3 | 2022 | 172 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 1999 | 137 | 0.150 |
Why?
|
| Sri Lanka | 1 | 2018 | 7 | 0.150 |
Why?
|
| Heterozygote | 6 | 2021 | 251 | 0.150 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 88 | 0.150 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 2 | 2008 | 57 | 0.150 |
Why?
|
| Rhodobacter sphaeroides | 1 | 1998 | 7 | 0.150 |
Why?
|
| ErbB Receptors | 1 | 2021 | 554 | 0.150 |
Why?
|
| Chemokine CXCL2 | 4 | 1999 | 41 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 139 | 0.150 |
Why?
|
| Sex Factors | 7 | 2018 | 1715 | 0.150 |
Why?
|
| Triamcinolone Acetonide | 1 | 1998 | 27 | 0.150 |
Why?
|
| Intestines | 1 | 2021 | 326 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2020 | 608 | 0.150 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 2785 | 0.150 |
Why?
|
| Protein Binding | 2 | 2017 | 1890 | 0.150 |
Why?
|
| Betaine | 1 | 2018 | 63 | 0.150 |
Why?
|
| Flow Cytometry | 3 | 2013 | 1083 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2017 | 11 | 0.150 |
Why?
|
| Adoptive Transfer | 3 | 2009 | 195 | 0.150 |
Why?
|
| Nicotine | 1 | 2020 | 265 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 535 | 0.140 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2017 | 41 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 718 | 0.140 |
Why?
|
| Fear | 1 | 2020 | 293 | 0.140 |
Why?
|
| Dinucleoside Phosphates | 1 | 1997 | 24 | 0.140 |
Why?
|
| Pentoxifylline | 1 | 1997 | 21 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2009 | 278 | 0.140 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 307 | 0.140 |
Why?
|
| Prognosis | 6 | 2019 | 3329 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 128 | 0.140 |
Why?
|
| Arrestins | 2 | 2009 | 14 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 75 | 0.140 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2017 | 64 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 651 | 0.140 |
Why?
|
| Blood | 3 | 2008 | 96 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1997 | 82 | 0.140 |
Why?
|
| Quality of Life | 4 | 2021 | 2353 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2019 | 594 | 0.140 |
Why?
|
| Incidence | 1 | 2023 | 2313 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 234 | 0.140 |
Why?
|
| Environmental Pollutants | 2 | 2011 | 110 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 680 | 0.130 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 112 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2012 | 923 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 299 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 44 | 0.130 |
Why?
|
| Chemokines | 3 | 2012 | 216 | 0.130 |
Why?
|
| Interferon-alpha | 1 | 1997 | 186 | 0.130 |
Why?
|
| Pulmonary Diffusing Capacity | 7 | 2005 | 60 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 3 | 2003 | 448 | 0.130 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 45 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2017 | 122 | 0.130 |
Why?
|
| Trypanosoma cruzi | 2 | 2015 | 23 | 0.130 |
Why?
|
| Hydrocortisone | 1 | 1998 | 267 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 349 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 211 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2007 | 127 | 0.130 |
Why?
|
| Global Health | 1 | 2018 | 287 | 0.130 |
Why?
|
| Carbon Monoxide | 2 | 2012 | 64 | 0.130 |
Why?
|
| Radiography | 5 | 2005 | 812 | 0.130 |
Why?
|
| Sus scrofa | 2 | 2021 | 45 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2009 | 298 | 0.130 |
Why?
|
| Risk | 3 | 2015 | 812 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 248 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2017 | 129 | 0.130 |
Why?
|
| Hospitals | 1 | 2020 | 581 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 139 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2008 | 119 | 0.130 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1995 | 33 | 0.120 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2015 | 5 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1342 | 0.120 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2014 | 10 | 0.120 |
Why?
|
| Trachea | 3 | 2009 | 224 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 313 | 0.120 |
Why?
|
| Computational Biology | 3 | 2009 | 530 | 0.120 |
Why?
|
| Bronchi | 4 | 2005 | 232 | 0.120 |
Why?
|
| Research | 4 | 2005 | 394 | 0.120 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.120 |
Why?
|
| Air Pollution | 1 | 2017 | 169 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 616 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2015 | 141 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2020 | 1373 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2012 | 75 | 0.120 |
Why?
|
| NF-kappa B | 3 | 2014 | 641 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 2 | 2013 | 396 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1121 | 0.120 |
Why?
|
| Algorithms | 2 | 2019 | 1468 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 398 | 0.120 |
Why?
|
| Gene-Environment Interaction | 2 | 2014 | 183 | 0.120 |
Why?
|
| Antigens, Protozoan | 2 | 2012 | 19 | 0.120 |
Why?
|
| Isoleucine | 1 | 2014 | 11 | 0.120 |
Why?
|
| Transplantation, Homologous | 2 | 2007 | 377 | 0.120 |
Why?
|
| Cell Division | 3 | 2004 | 758 | 0.110 |
Why?
|
| Threonine | 1 | 2014 | 40 | 0.110 |
Why?
|
| Interleukins | 1 | 1996 | 236 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2016 | 1019 | 0.110 |
Why?
|
| Veterans | 3 | 2004 | 1249 | 0.110 |
Why?
|
| Cluster Analysis | 4 | 2022 | 455 | 0.110 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2013 | 11 | 0.110 |
Why?
|
| Homeostasis | 3 | 2009 | 573 | 0.110 |
Why?
|
| Peptide Elongation Factors | 1 | 2013 | 13 | 0.110 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2013 | 10 | 0.110 |
Why?
|
| beta-Lactamases | 2 | 2005 | 25 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2011 | 1692 | 0.110 |
Why?
|
| Vaccination | 1 | 2022 | 1204 | 0.110 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1994 | 58 | 0.110 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2013 | 57 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 1998 | 532 | 0.110 |
Why?
|
| Vehicle Emissions | 1 | 2013 | 48 | 0.110 |
Why?
|
| HLA-A Antigens | 1 | 1993 | 49 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 184 | 0.110 |
Why?
|
| Saskatchewan | 3 | 2021 | 7 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 683 | 0.110 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 313 | 0.110 |
Why?
|
| Apoptosis | 3 | 2023 | 2363 | 0.110 |
Why?
|
| HLA-B Antigens | 1 | 1993 | 56 | 0.110 |
Why?
|
| Chromosomes, Human | 1 | 2013 | 39 | 0.110 |
Why?
|
| Iowa | 4 | 2004 | 24 | 0.110 |
Why?
|
| Coal Ash | 2 | 2004 | 4 | 0.110 |
Why?
|
| Pulmonary Surfactants | 3 | 2016 | 99 | 0.100 |
Why?
|
| Physical Exertion | 1 | 1994 | 209 | 0.100 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 34 | 0.100 |
Why?
|
| Biology | 2 | 2023 | 79 | 0.100 |
Why?
|
| HLA-DQ Antigens | 1 | 1993 | 174 | 0.100 |
Why?
|
| Macrophage Activation | 3 | 2011 | 164 | 0.100 |
Why?
|
| Methotrexate | 3 | 2021 | 226 | 0.100 |
Why?
|
| Solubility | 2 | 2017 | 223 | 0.100 |
Why?
|
| Child, Preschool | 5 | 2022 | 9114 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2010 | 243 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 1993 | 219 | 0.100 |
Why?
|
| H-2 Antigens | 1 | 2012 | 110 | 0.100 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 267 | 0.100 |
Why?
|
| Cell Separation | 1 | 2013 | 291 | 0.100 |
Why?
|
| Histamine | 1 | 1992 | 56 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 295 | 0.100 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 53 | 0.100 |
Why?
|
| Aluminum Silicates | 1 | 1991 | 11 | 0.100 |
Why?
|
| Europe | 3 | 2022 | 334 | 0.100 |
Why?
|
| Sample Size | 2 | 2022 | 112 | 0.100 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 18 | 0.100 |
Why?
|
| Carbon | 2 | 2004 | 156 | 0.100 |
Why?
|
| Collagen | 2 | 2006 | 415 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2021 | 562 | 0.100 |
Why?
|
| Amino Acid Sequence | 4 | 2011 | 1982 | 0.100 |
Why?
|
| Pulmonary Ventilation | 3 | 1997 | 72 | 0.090 |
Why?
|
| beta-Lactam Resistance | 1 | 2011 | 6 | 0.090 |
Why?
|
| Cross-Over Studies | 3 | 1998 | 440 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 497 | 0.090 |
Why?
|
| Myocarditis | 1 | 2012 | 93 | 0.090 |
Why?
|
| Nitric Oxide | 3 | 2014 | 823 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 380 | 0.090 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 100 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 195 | 0.090 |
Why?
|
| Proteomics | 3 | 2017 | 836 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2014 | 432 | 0.090 |
Why?
|
| Depression | 1 | 2018 | 1134 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2011 | 155 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 2177 | 0.090 |
Why?
|
| Haplotypes | 3 | 2021 | 448 | 0.090 |
Why?
|
| Caspases | 1 | 2011 | 245 | 0.090 |
Why?
|
| Accidents, Occupational | 1 | 1990 | 14 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2023 | 687 | 0.090 |
Why?
|
| Gases | 1 | 1990 | 37 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 366 | 0.090 |
Why?
|
| Serratia marcescens | 1 | 2009 | 12 | 0.090 |
Why?
|
| Paternal Age | 1 | 1989 | 2 | 0.090 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2010 | 40 | 0.080 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 4408 | 0.080 |
Why?
|
| Chlorine | 1 | 1990 | 62 | 0.080 |
Why?
|
| Cross Infection | 2 | 2010 | 197 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2009 | 68 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 299 | 0.080 |
Why?
|
| Growth Substances | 1 | 1989 | 138 | 0.080 |
Why?
|
| Metallothionein | 1 | 2009 | 24 | 0.080 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2012 | 130 | 0.080 |
Why?
|
| Pyroglyphidae | 2 | 2023 | 17 | 0.080 |
Why?
|
| Iceland | 2 | 2019 | 6 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 170 | 0.080 |
Why?
|
| Genome | 1 | 2011 | 271 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 260 | 0.080 |
Why?
|
| Feces | 1 | 2011 | 373 | 0.080 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2009 | 101 | 0.080 |
Why?
|
| Mice, Inbred NZB | 1 | 2008 | 15 | 0.080 |
Why?
|
| Mice, Inbred AKR | 1 | 2008 | 34 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 1796 | 0.080 |
Why?
|
| Nitric Oxide Synthase | 2 | 2006 | 209 | 0.080 |
Why?
|
| Mice, Inbred A | 1 | 2008 | 45 | 0.080 |
Why?
|
| Gene Library | 1 | 2008 | 114 | 0.080 |
Why?
|
| Mycology | 1 | 2008 | 3 | 0.080 |
Why?
|
| Fungemia | 1 | 2008 | 3 | 0.080 |
Why?
|
| Recurrence | 2 | 2021 | 935 | 0.080 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2008 | 37 | 0.080 |
Why?
|
| Bacteria | 1 | 2014 | 725 | 0.080 |
Why?
|
| Software | 1 | 2012 | 530 | 0.080 |
Why?
|
| Procollagen | 1 | 2008 | 19 | 0.080 |
Why?
|
| Aspergillus fumigatus | 1 | 2008 | 20 | 0.080 |
Why?
|
| Liver | 3 | 2012 | 1637 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2013 | 808 | 0.080 |
Why?
|
| Candida | 1 | 2008 | 32 | 0.080 |
Why?
|
| Germ-Line Mutation | 2 | 2020 | 130 | 0.080 |
Why?
|
| Candidiasis | 1 | 2008 | 51 | 0.080 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 152 | 0.080 |
Why?
|
| Paint | 1 | 1988 | 7 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 955 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 32 | 0.070 |
Why?
|
| Brachiocephalic Veins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 109 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 79 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2007 | 7 | 0.070 |
Why?
|
| Chemotactic Factors | 2 | 1998 | 50 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2007 | 45 | 0.070 |
Why?
|
| Bronchoscopy | 3 | 2014 | 245 | 0.070 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2007 | 15 | 0.070 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 101 | 0.070 |
Why?
|
| Recombination, Genetic | 2 | 2005 | 176 | 0.070 |
Why?
|
| Azacitidine | 1 | 2008 | 129 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2007 | 35 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 1214 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 1230 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2018 | 663 | 0.070 |
Why?
|
| Dinoprostone | 2 | 2001 | 184 | 0.070 |
Why?
|
| Lung Compliance | 1 | 2007 | 47 | 0.070 |
Why?
|
| Placebos | 2 | 1998 | 197 | 0.070 |
Why?
|
| Cytokinesis | 1 | 2007 | 46 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 849 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 105 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 1998 | 258 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2015 | 1958 | 0.070 |
Why?
|
| Arm | 1 | 2007 | 104 | 0.070 |
Why?
|
| Aerosols | 2 | 2001 | 150 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 75 | 0.070 |
Why?
|
| Neutrophil Activation | 1 | 2007 | 94 | 0.070 |
Why?
|
| Crosses, Genetic | 2 | 2011 | 139 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 60 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 201 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2007 | 268 | 0.070 |
Why?
|
| Monocytes | 1 | 1989 | 504 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 638 | 0.070 |
Why?
|
| Lymphokines | 1 | 2006 | 111 | 0.070 |
Why?
|
| Chemokine CXCL12 | 1 | 2006 | 74 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2007 | 176 | 0.070 |
Why?
|
| Chimera | 1 | 2006 | 59 | 0.070 |
Why?
|
| Cell Count | 2 | 1998 | 303 | 0.070 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 78 | 0.070 |
Why?
|
| Nitrites | 1 | 2006 | 75 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 343 | 0.070 |
Why?
|
| Ear, Middle | 2 | 2018 | 89 | 0.060 |
Why?
|
| Models, Biological | 3 | 2013 | 1620 | 0.060 |
Why?
|
| Response Elements | 1 | 2006 | 82 | 0.060 |
Why?
|
| Postal Service | 2 | 1996 | 29 | 0.060 |
Why?
|
| Learning | 1 | 1989 | 350 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2007 | 785 | 0.060 |
Why?
|
| Agar | 2 | 2018 | 11 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2005 | 73 | 0.060 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 1737 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2006 | 184 | 0.060 |
Why?
|
| Rural Population | 1 | 2009 | 446 | 0.060 |
Why?
|
| S-Nitrosoglutathione | 1 | 2005 | 6 | 0.060 |
Why?
|
| S-Nitrosothiols | 1 | 2005 | 4 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2006 | 134 | 0.060 |
Why?
|
| Glutathione Reductase | 1 | 2005 | 21 | 0.060 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2005 | 104 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2020 | 525 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2009 | 1076 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2009 | 1569 | 0.060 |
Why?
|
| Interferons | 1 | 2006 | 151 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 750 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2006 | 289 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2004 | 758 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 208 | 0.060 |
Why?
|
| Transplantation, Heterotopic | 1 | 2005 | 16 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2000 | 392 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2005 | 262 | 0.060 |
Why?
|
| Chimerism | 1 | 2004 | 28 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2023 | 522 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2003 | 271 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 306 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2008 | 430 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 133 | 0.060 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2005 | 52 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2004 | 50 | 0.060 |
Why?
|
| Sputum | 2 | 1997 | 285 | 0.060 |
Why?
|
| Peroxidase | 1 | 2004 | 163 | 0.060 |
Why?
|
| Reference Values | 2 | 2000 | 743 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2016 | 249 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 136 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 280 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2005 | 108 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2004 | 56 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 2004 | 115 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2004 | 29 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2005 | 182 | 0.060 |
Why?
|
| Lakes | 1 | 2024 | 28 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 289 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2007 | 374 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 800 | 0.060 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2003 | 5 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2007 | 1037 | 0.060 |
Why?
|
| Plethysmography | 1 | 2004 | 103 | 0.060 |
Why?
|
| DNA, Protozoan | 1 | 2003 | 26 | 0.060 |
Why?
|
| Neoplasms | 1 | 2017 | 2097 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2004 | 158 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 411 | 0.050 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
|
| Bronchitis, Chronic | 1 | 2003 | 17 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2003 | 67 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2003 | 30 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 591 | 0.050 |
Why?
|
| DNA Damage | 1 | 2005 | 351 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1394 | 0.050 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2003 | 83 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 1994 | 217 | 0.050 |
Why?
|
| Serotonin | 1 | 2005 | 292 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 16 | 0.050 |
Why?
|
| Prednisone | 2 | 1994 | 229 | 0.050 |
Why?
|
| Skin Tests | 2 | 2008 | 116 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2010 | 157 | 0.050 |
Why?
|
| Proteolipids | 1 | 2002 | 28 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 489 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 171 | 0.050 |
Why?
|
| Heart Rate | 1 | 2006 | 709 | 0.050 |
Why?
|
| Wound Healing | 1 | 2004 | 258 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 57 | 0.050 |
Why?
|
| Combat Disorders | 1 | 2002 | 33 | 0.050 |
Why?
|
| Pulmonary Medicine | 1 | 2003 | 87 | 0.050 |
Why?
|
| Intestinal Fistula | 1 | 2021 | 11 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 103 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 22 | 0.050 |
Why?
|
| Cutaneous Fistula | 1 | 2021 | 13 | 0.050 |
Why?
|
| Myofibroblasts | 1 | 2023 | 116 | 0.050 |
Why?
|
| Cyclooxygenase 1 | 1 | 2001 | 20 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 213 | 0.050 |
Why?
|
| Intestinal Polyps | 1 | 2021 | 15 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2001 | 48 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 97 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 144 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 27 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2005 | 301 | 0.050 |
Why?
|
| Staphylococcus aureus | 2 | 2016 | 389 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2004 | 382 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 12 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 1999 | 198 | 0.050 |
Why?
|
| Anatomic Landmarks | 1 | 2021 | 23 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 303 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2001 | 146 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2001 | 49 | 0.050 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Lac Operon | 1 | 2001 | 44 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2002 | 180 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2021 | 52 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2001 | 164 | 0.050 |
Why?
|
| alpha Karyopherins | 1 | 2020 | 13 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2021 | 51 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2004 | 529 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2021 | 136 | 0.050 |
Why?
|
| Tripartite Motif Proteins | 1 | 2020 | 30 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 144 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 25 | 0.040 |
Why?
|
| Middle East | 1 | 2000 | 10 | 0.040 |
Why?
|
| Population Density | 1 | 2021 | 94 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 94 | 0.040 |
Why?
|
| Linear Models | 2 | 2015 | 768 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2020 | 49 | 0.040 |
Why?
|
| Bronchitis | 1 | 2000 | 35 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2021 | 168 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 222 | 0.040 |
Why?
|
| Telephone | 1 | 2021 | 152 | 0.040 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Varenicline | 1 | 2020 | 22 | 0.040 |
Why?
|
| Bupropion | 1 | 2020 | 39 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2187 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 430 | 0.040 |
Why?
|
| beta Karyopherins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Faculty | 1 | 2021 | 130 | 0.040 |
Why?
|
| Trichinellosis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Trichinella spiralis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cross Protection | 1 | 2019 | 4 | 0.040 |
Why?
|
| Mitochondria | 1 | 2005 | 747 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 151 | 0.040 |
Why?
|
| Goblet Cells | 1 | 2019 | 16 | 0.040 |
Why?
|
| Point Mutation | 1 | 2000 | 216 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2017 | 379 | 0.040 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2013 | 90 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 243 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2004 | 520 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2000 | 257 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2006 | 1538 | 0.040 |
Why?
|
| Biopsy | 4 | 2012 | 1036 | 0.040 |
Why?
|
| Philippines | 1 | 2019 | 50 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 173 | 0.040 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 87 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 227 | 0.040 |
Why?
|
| Pakistan | 1 | 2019 | 73 | 0.040 |
Why?
|
| Finland | 1 | 2019 | 69 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 163 | 0.040 |
Why?
|
| Rural Health | 1 | 1999 | 67 | 0.040 |
Why?
|
| Virus Physiological Phenomena | 1 | 2018 | 6 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 634 | 0.040 |
Why?
|
| Gastric Acidity Determination | 1 | 1998 | 7 | 0.040 |
Why?
|
| Stem Cells | 1 | 2023 | 546 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 381 | 0.040 |
Why?
|
| Family | 1 | 2022 | 589 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 1998 | 24 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2021 | 228 | 0.040 |
Why?
|
| Homozygote | 2 | 2009 | 187 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 1998 | 44 | 0.040 |
Why?
|
| COS Cells | 1 | 2018 | 175 | 0.040 |
Why?
|
| Stomach | 1 | 1998 | 102 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 847 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 620 | 0.040 |
Why?
|
| Environmental Pollution | 1 | 2018 | 17 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 36 | 0.040 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 57 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2011 | 14 | 0.040 |
Why?
|
| Leadership | 1 | 2021 | 292 | 0.040 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2017 | 6 | 0.040 |
Why?
|
| Schools | 1 | 2021 | 399 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 25 | 0.040 |
Why?
|
| Conscious Sedation | 1 | 1998 | 78 | 0.040 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2017 | 19 | 0.040 |
Why?
|
| Maternal Health | 1 | 2018 | 42 | 0.040 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2017 | 73 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 2 | 1995 | 117 | 0.040 |
Why?
|
| Chromatin | 1 | 2021 | 428 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 358 | 0.040 |
Why?
|
| beta-Arrestin 2 | 2 | 2009 | 4 | 0.040 |
Why?
|
| Workflow | 1 | 2018 | 133 | 0.040 |
Why?
|
| Fasting | 1 | 1998 | 240 | 0.040 |
Why?
|
| beta-Arrestins | 2 | 2009 | 12 | 0.040 |
Why?
|
| Military Personnel | 2 | 2004 | 524 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 371 | 0.030 |
Why?
|
| Carrier State | 1 | 1997 | 54 | 0.030 |
Why?
|
| Penicillamine | 1 | 1996 | 22 | 0.030 |
Why?
|
| Folic Acid | 1 | 2018 | 161 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1998 | 182 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 218 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 3046 | 0.030 |
Why?
|
| Polymyxin B | 1 | 1996 | 21 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 82 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2010 | 617 | 0.030 |
Why?
|
| Chemical Fractionation | 1 | 1996 | 28 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 330 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2016 | 79 | 0.030 |
Why?
|
| Text Messaging | 1 | 2018 | 152 | 0.030 |
Why?
|
| Child Health | 1 | 2018 | 127 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 56 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 344 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2020 | 551 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 510 | 0.030 |
Why?
|
| Stents | 1 | 2020 | 475 | 0.030 |
Why?
|
| Microspheres | 1 | 1996 | 123 | 0.030 |
Why?
|
| ADAMTS9 Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2015 | 8 | 0.030 |
Why?
|
| ADAMTS4 Protein | 1 | 2015 | 15 | 0.030 |
Why?
|
| Serpins | 1 | 2015 | 25 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 53 | 0.030 |
Why?
|
| Kinetics | 1 | 1999 | 1551 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 184 | 0.030 |
Why?
|
| Gold | 1 | 1996 | 106 | 0.030 |
Why?
|
| Emphysema | 1 | 2016 | 107 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 58 | 0.030 |
Why?
|
| Aspergillus oryzae | 1 | 2015 | 3 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 2128 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 27 | 0.030 |
Why?
|
| Agriculture | 1 | 1995 | 72 | 0.030 |
Why?
|
| Dermatophagoides pteronyssinus | 1 | 2014 | 3 | 0.030 |
Why?
|
| Residual Volume | 2 | 1995 | 5 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 532 | 0.030 |
Why?
|
| Blood Cells | 1 | 2014 | 38 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 331 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 1995 | 110 | 0.030 |
Why?
|
| Cough | 1 | 1995 | 107 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 69 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 162 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2014 | 58 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1996 | 154 | 0.030 |
Why?
|
| Respiratory Dead Space | 1 | 1994 | 2 | 0.030 |
Why?
|
| Genetics | 1 | 2014 | 27 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1994 | 78 | 0.030 |
Why?
|
| Mass Chest X-Ray | 1 | 1994 | 4 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 28 | 0.030 |
Why?
|
| Random Allocation | 1 | 1995 | 335 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1314 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 39 | 0.030 |
Why?
|
| HLA-B44 Antigen | 1 | 1993 | 2 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 770 | 0.030 |
Why?
|
| HLA-DRB4 Chains | 1 | 1993 | 6 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 1993 | 39 | 0.030 |
Why?
|
| Remission Induction | 1 | 1994 | 233 | 0.030 |
Why?
|
| Brain | 1 | 2005 | 2371 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2013 | 104 | 0.030 |
Why?
|
| Equipment Design | 1 | 1995 | 508 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 763 | 0.030 |
Why?
|
| APACHE | 1 | 2013 | 58 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 1994 | 292 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 219 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 529 | 0.030 |
Why?
|
| Fibronectins | 1 | 1993 | 108 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2012 | 11 | 0.030 |
Why?
|
| Urine | 1 | 1993 | 54 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2012 | 29 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1994 | 233 | 0.030 |
Why?
|
| DNA Probes | 1 | 2012 | 59 | 0.030 |
Why?
|
| Programming Languages | 1 | 2012 | 22 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 190 | 0.030 |
Why?
|
| Latin America | 1 | 2012 | 69 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 149 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2013 | 187 | 0.020 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 44 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2013 | 98 | 0.020 |
Why?
|
| Functional Residual Capacity | 1 | 1991 | 7 | 0.020 |
Why?
|
| Mast Cells | 1 | 1992 | 116 | 0.020 |
Why?
|
| Education | 1 | 2012 | 95 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 159 | 0.020 |
Why?
|
| Antigens | 1 | 2013 | 318 | 0.020 |
Why?
|
| Poly I-C | 1 | 2011 | 51 | 0.020 |
Why?
|
| Arthropod Proteins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1993 | 134 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 356 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2011 | 60 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 445 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 411 | 0.020 |
Why?
|
| Greece | 1 | 2010 | 7 | 0.020 |
Why?
|
| Listeriosis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Metallurgy | 1 | 1990 | 8 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 84 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 323 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 29 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2009 | 11 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2011 | 111 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 289 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 194 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 276 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 187 | 0.020 |
Why?
|
| Thrombosis | 1 | 2012 | 298 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2012 | 416 | 0.020 |
Why?
|
| Resuscitation | 1 | 1991 | 252 | 0.020 |
Why?
|
| Helium | 1 | 2007 | 6 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2009 | 206 | 0.020 |
Why?
|
| Particle Size | 1 | 2009 | 317 | 0.020 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 24 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 270 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 443 | 0.020 |
Why?
|
| Rats | 2 | 2006 | 4958 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 81 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 288 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2007 | 139 | 0.020 |
Why?
|
| Psychometrics | 1 | 1989 | 608 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 387 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 1727 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 424 | 0.020 |
Why?
|
| Imines | 1 | 2005 | 7 | 0.020 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 15 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2005 | 20 | 0.020 |
Why?
|
| Cephalosporin Resistance | 1 | 2005 | 1 | 0.020 |
Why?
|
| Cefotaxime | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ceftazidime | 1 | 2005 | 5 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2005 | 37 | 0.020 |
Why?
|
| Isoproterenol | 1 | 2005 | 106 | 0.020 |
Why?
|
| Histidine | 1 | 2005 | 57 | 0.010 |
Why?
|
| Aging | 1 | 2014 | 1618 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 126 | 0.010 |
Why?
|
| Laboratories | 1 | 2005 | 95 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2003 | 18 | 0.010 |
Why?
|
| Genes, Protozoan | 1 | 2003 | 10 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 134 | 0.010 |
Why?
|
| Peptides | 1 | 2009 | 848 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 238 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 2005 | 239 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 361 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2003 | 62 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2003 | 92 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2003 | 123 | 0.010 |
Why?
|
| Israel | 1 | 2003 | 40 | 0.010 |
Why?
|
| Microbiological Techniques | 1 | 2003 | 29 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2003 | 42 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2003 | 130 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 205 | 0.010 |
Why?
|
| Calcium | 1 | 2007 | 1108 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2001 | 62 | 0.010 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2001 | 24 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 138 | 0.010 |
Why?
|
| Internet | 1 | 2005 | 596 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 253 | 0.010 |
Why?
|
| Clone Cells | 1 | 2001 | 247 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 796 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 2004 | 319 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 680 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 1448 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 959 | 0.010 |
Why?
|
| Lung Volume Measurements | 1 | 1997 | 45 | 0.010 |
Why?
|
| Organ Size | 1 | 1997 | 434 | 0.010 |
Why?
|
| Proteus | 1 | 1993 | 6 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1993 | 26 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 111 | 0.010 |
Why?
|
| Klebsiella pneumoniae | 1 | 1993 | 41 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 4622 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1993 | 728 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 1226 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1993 | 951 | 0.010 |
Why?
|